Global Differences in the Outcome of Heart Failure. Implications for Clinical Practice

Journal of the American College of Cardiology

Volumn 52, Issue 20, 2008, Pages 1649-1651

  Poole Wilson, Philip A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

heart failure; outcomes; regional differences

Indexed keywords

TOLVAPTAN;

CARDIOVASCULAR DISEASE; DISEASE SEVERITY; EDITORIAL; ETHNICITY; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART SIZE; HOSPITALIZATION; HUMAN; MEDICAL PRACTICE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

HEART FAILURE; HUMANS; INTERNATIONALITY; PHYSICIAN'S PRACTICE PATTERNS;

EID: 55049107087     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.08.022     Document Type: Editorial

References (34)

1. SIGN. Scottish Intercollegiate Guidelines Network. 95 Management of Chronic Heart Failure. A National Clinical Guideline. 1-55 (2007). http://www.sign.ac.uk Accessed February 20, 2007
2. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) 1116-1143
3. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
4. Arnold J.M., Howlett J.G., Dorian P., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 23 (2007) 21-45
5. Krum H., Jelinek M.V., Stewart S., Sindone A., Atherton J.J., and Hawkes A.L. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 185 (2006) 549-557
6. Komajda M., Lapuerta P., Hermans N., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26 (2005) 1653-1659
7. Granger B.B., Swedberg K., Ekman I., et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366 (2005) 2005-2011
8. Van de Werf, Topol E.J., Lee K.L., et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA 273 (1995) 1586-1591
9. Fox K.A., Goodman S., Bigonzi F., Le Iouer V., and Cohen M. Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. Eur Heart J 21 (2000) 1433-1439
10. Domanski M., Antman E.M., McKinlay S., et al. Geographic variability in patient characteristics, treatment and outcome in an international trial of magnesium in acute myocardial infarction. Control Clin Trials 25 (2004) 553-562
11. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003) 464-474
12. Poole-Wilson P.A. Differences in European and North American approaches to the management of heart failure. Cardiol Clin 26 (2008) 107-112
13. Rothwell P.M. Treating individuals 2: subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005) 176-186
14. ISIS-2 (Second International Study of Infarct Survival) Collaboration Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarctions: ISIS-2. Lancet 2 (1988) 349-360
15. Parameshwar J., Keegan J., Sparrow J., Sutton G.C., and Poole-Wilson P.A. Predictors of prognosis in severe heart failure. Am Heart J 123 (1992) 421-426
16. Frazier C.G., Alexander K.P., Newby L.K., et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol 49 (2007) 1450-1458
17. Clayton T.C., Pocock S.J., Henderson R.A., et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction?. The impact of gender in the RITA 3 trial. Eur Heart J 25 (2004) 1641-1650
18. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113 (2006) 1424-1433
19. Blair J.E.A., Zannad F., Konstam M.A., et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure: results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 52 (2008) 1640-1648
20. Massie B.M., Cleland J.G., Armstrong P.W., et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. (erratum appears in J Card Fail 1998;4:153). J Card Fail 4 (1998) 3-8
21. Duster T. Medicalisation of race. Lancet 369 (2007) 702-704
22. Yancy C.W., Fowler M.B., Colucci W.S., et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 (2001) 1358-1365
23. Wood A.J. Racial differences in the response to drugs-pointers to genetic differences. N Engl J Med 344 (2001) 1394-1396
24. Exner D.V., Dries D.L., Domanski M.J., and Cohn J.N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
25. Prisant L.M., Thomas K.L., Lewis E.F., et al. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. J Am Coll Cardiol 51 (2008) 1865-1871
26. Mathew J., Wittes J., McSherry F., et al. Racial differences in outcome and treatment effect in congestive heart failure. Am Heart J 150 (2005) 968-976
27. Mitchell J.E., Hellkamp A.S., Mark D.B., et al. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 155 (2008) 501-506
28. Abraham W.T., Massie B.M., Lukas M.A., et al. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Congest Heart Fail 13 (2007) 16-21
29. Rothwell P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 365 (2005) 82-93
30. Berwick D.M. A transatlantic review of the NHS at 60. Br Med J 337 (2008) a838
31. Why Not the Best?. Results from the National Scorecard on US Health System Performance, 2008. http://www.commonwealthfund.org Accessed August 1, 2008
32. Lee D.S., Johansen H., Gong Y., Hall R.E., Tu J.V., and Cox J.L. Regional outcomes of heart failure in Canada. Can J Cardiol 20 (2004) 599-607
33. Euro Consumer Heart Index 2008. http://www.healthpowerhouse.com/archives/cat_media_room.html Accessed July 30, 2008
34. FDA Advisory Panel Rejects K-Channel Blocker for AF Cardioversion. http://www.heart.org/article/833525.do Accessed July 28, 2008